Latest Mei Pharma Inc (MEIP) Headlines 4 Stocks
Post# of 63
Posted On: 03/13/2014 11:00:05 AM
Latest Mei Pharma Inc (MEIP) Headlines
4 Stocks Under $10 Triggering Breakouts
at The Street - Fri Mar 07, 5:00AM CST
These under-$10 stocks are within range of triggering breakout trades.
MEI Pharma (MEIP) is Overbought, What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:21AM CST
MEI Pharma (MEIP) is Overbought, What’s Next?
MEI Pharma Receives Orphan Status For Lead Drug Candidate Pracinostat For Treatment Of Acute Myeloid Leukemia
PR Newswire - Fri Feb 28, 7:33AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's investigational drug Pracinostat for the treatment of acute myeloid leukemia (AML).
MEI Pharma To Present At Cowen Health Care And ROTH Conferences
PR Newswire - Tue Feb 25, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:
Evidera And Symphony Technology Group Announce Appointment Of Simon Kennedy To Senior Leadership Roles
PR Newswire - Tue Feb 11, 8:00AM CST
Evidera, a leading provider of evidence-based solutions for the healthcare industry, and Symphony Technology Group (STG) (STG), a strategic private equity firm, today announced that Simon Kennedy has joined Evidera as executive chairman of the board, effective January 1. In this position, he plays a leadership role in defining Evidera's acquisition, new product development and overall growth strategies, working closely with Evidera's management team. Kennedy has also joined STG as healthcare operations partner, and another portfolio company, Symphony Health Solutions, as a member of the board of directors.
5 Stocks Ready to Break Out
at The Street - Fri Jan 31, 12:59PM CST
These stocks look ready to break out and trade higher from current levels.
Atlantic Power Corporation Announces Launch by Atlantic Power Limited Partnership of Syndication of New Senior Secured Credit Facilities
PR Newswire - Thu Jan 30, 7:30AM CST
Atlantic Power Corporation (TSX: ATP; NYSE: AT) (the "Company"), today announced that, as part of the Company's ongoing plans to address its upcoming debt maturities and improve its financial flexibility, Atlantic Power Limited Partnership ("APLP"), a wholly-owned indirect subsidiary of the Company, launched the syndication of new senior secured credit facilities, comprising up to $600 million in aggregate principal amount of senior secured term loan facilities and up to $200 million in aggregate principal amount of senior secured revolving credit facilities (collectively, the "new credit facilities"). The Company and its subsidiaries expect to use the new credit facilities to:
4 Biotech Stocks Under $10 Making Big Moves
at The Street - Wed Jan 29, 6:00AM CST
Keep these under-$10 biotech stocks on your radar.
'Why De-Registered Parties Joined PDP'
by Misbahu Bashir - All Africa Global Media - Tue Jan 21, 3:32AM CST
Chairman of the defunct United Nigeria Peoples Party (UNPP) Alhaji Inuwa Ahmed, yesterday at a media briefing in Kaduna explained why 23 de-registered political parties joined the ruling People's Democratic Party (PDP).
Pipeline Progress at MEI Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 15, 4:30PM CST
MEI Pharma announced that it has dosed the first patient in its phase II study on its pipeline candidate pracinostat for the treatment of patients with MDS
MEI Pharma Inc begins Phase II clinical trial of Pracinostat in refractory myelodysplastic syndrome
M2 - Wed Jan 15, 11:03AM CST
Oncology company MEI Pharma Inc (NasdaqCM:MEIP) reported on Tuesday the dosing of the first patient in a Phase II clinical trial of Pracinostat in patients with myelodysplastic syndrome (MDS).
MEI Pharma Initiates Phase II Clinical Trial Of Pracinostat In Refractory Myelodysplastic Syndrome
PR Newswire - Tue Jan 14, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patient has been dosed in a Phase II clinical trial of Pracinostat, the Company's investigational oral histone deacetylase (HDAC) inhibitor, in patients with myelodysplastic syndrome (MDS) who either failed to respond or maintain a response to a hypomethylating agent (HMA) alone.
Moving Average Crossover: Great News for MEI Pharma Inc. (MEIP)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 06, 7:44AM CST
Moving Average Crossover: Great News for MEI Pharma Inc. (MEIP)?
Fluids Simulation Advancements In ANSYS 15.0 Bring Faster and More Accurate Results to Users
PR Newswire - Fri Dec 20, 6:25AM CST
With faster pre-processing, solver and optimization technologies, users of ANSYS Inc.'s (NASDAQ: ANSS) release 15.0 for fluid dynamics simulation will be able to meet tighter development deadlines and further reduce time to market.
4 Stocks Under $10 to Trade for Breakouts
at The Street - Fri Dec 06, 6:00AM CST
These under-$10 stocks are within range of triggering breakout trades.
MEI Pharma To Host Analyst And Investor Day
PR Newswire - Thu Dec 05, 7:30AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, will host an Analyst and Investor Day on Thursday, December 11, 2013 from 12:00 noon to 2:00 p.m. Eastern time in New York City. The event will feature updates by Daniel P. Gold, Ph.D., President and Chief Executive Officer, and Robert D. Mass, MD, Chief Medical Officer, on the Company's clinical development programs for its lead oncology drug candidates, Pracinostat and ME-344, along with presentations by Dr. Guillermo Garcia-Manero of the MD Anderson Cancer Center and Dr. Jeffrey R. Infante of the Sarah Cannon Research Institute and Tennessee Oncology. A live webcast of the event will be accessible at www.meipharma.com/investor. A replay will be available approximately one hour after its conclusion.
MEI Pharma To Host Annual Meeting Of Stockholders
PR Newswire - Tue Nov 26, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, will host its Annual Meeting of Stockholders at 10:00 a.m. Central time on Thursday, December 5, 2013 at the W New Orleans, 333 Poydras Street, New Orleans, LA 70130, to consider and vote on certain matters, including the election of three directors, the ratification of the appointment of the Company's independent registered public accounting firm and approval, on an advisory basis, of the compensation of the Company's named executive officers. A live webcast of the meeting will be accessible at www.meipharma.com/investor. A replay will be available approximately one hour after the presentation.
4 Stocks Under $10 Making Big Moves
at The Street - Tue Nov 19, 7:58PM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
MEI Pharma Inc prices public offering at USD8.00 per share
M2 - Mon Oct 28, 6:51AM CDT
Oncology company MEI Pharma Inc (NasdaqCM:MEIP) said on Friday that it has priced an underwritten public offering of 4,375,000 shares of its common stock.
Nasdaq stocks posting largest percentage decreases
AP - Fri Oct 25, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
4 Stocks Under $10 Triggering Breakouts
at The Street - Fri Mar 07, 5:00AM CST
These under-$10 stocks are within range of triggering breakout trades.
MEI Pharma (MEIP) is Overbought, What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 8:21AM CST
MEI Pharma (MEIP) is Overbought, What’s Next?
MEI Pharma Receives Orphan Status For Lead Drug Candidate Pracinostat For Treatment Of Acute Myeloid Leukemia
PR Newswire - Fri Feb 28, 7:33AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's investigational drug Pracinostat for the treatment of acute myeloid leukemia (AML).
MEI Pharma To Present At Cowen Health Care And ROTH Conferences
PR Newswire - Tue Feb 25, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:
Evidera And Symphony Technology Group Announce Appointment Of Simon Kennedy To Senior Leadership Roles
PR Newswire - Tue Feb 11, 8:00AM CST
Evidera, a leading provider of evidence-based solutions for the healthcare industry, and Symphony Technology Group (STG) (STG), a strategic private equity firm, today announced that Simon Kennedy has joined Evidera as executive chairman of the board, effective January 1. In this position, he plays a leadership role in defining Evidera's acquisition, new product development and overall growth strategies, working closely with Evidera's management team. Kennedy has also joined STG as healthcare operations partner, and another portfolio company, Symphony Health Solutions, as a member of the board of directors.
5 Stocks Ready to Break Out
at The Street - Fri Jan 31, 12:59PM CST
These stocks look ready to break out and trade higher from current levels.
Atlantic Power Corporation Announces Launch by Atlantic Power Limited Partnership of Syndication of New Senior Secured Credit Facilities
PR Newswire - Thu Jan 30, 7:30AM CST
Atlantic Power Corporation (TSX: ATP; NYSE: AT) (the "Company"), today announced that, as part of the Company's ongoing plans to address its upcoming debt maturities and improve its financial flexibility, Atlantic Power Limited Partnership ("APLP"), a wholly-owned indirect subsidiary of the Company, launched the syndication of new senior secured credit facilities, comprising up to $600 million in aggregate principal amount of senior secured term loan facilities and up to $200 million in aggregate principal amount of senior secured revolving credit facilities (collectively, the "new credit facilities"). The Company and its subsidiaries expect to use the new credit facilities to:
4 Biotech Stocks Under $10 Making Big Moves
at The Street - Wed Jan 29, 6:00AM CST
Keep these under-$10 biotech stocks on your radar.
'Why De-Registered Parties Joined PDP'
by Misbahu Bashir - All Africa Global Media - Tue Jan 21, 3:32AM CST
Chairman of the defunct United Nigeria Peoples Party (UNPP) Alhaji Inuwa Ahmed, yesterday at a media briefing in Kaduna explained why 23 de-registered political parties joined the ruling People's Democratic Party (PDP).
Pipeline Progress at MEI Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 15, 4:30PM CST
MEI Pharma announced that it has dosed the first patient in its phase II study on its pipeline candidate pracinostat for the treatment of patients with MDS
MEI Pharma Inc begins Phase II clinical trial of Pracinostat in refractory myelodysplastic syndrome
M2 - Wed Jan 15, 11:03AM CST
Oncology company MEI Pharma Inc (NasdaqCM:MEIP) reported on Tuesday the dosing of the first patient in a Phase II clinical trial of Pracinostat in patients with myelodysplastic syndrome (MDS).
MEI Pharma Initiates Phase II Clinical Trial Of Pracinostat In Refractory Myelodysplastic Syndrome
PR Newswire - Tue Jan 14, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the first patient has been dosed in a Phase II clinical trial of Pracinostat, the Company's investigational oral histone deacetylase (HDAC) inhibitor, in patients with myelodysplastic syndrome (MDS) who either failed to respond or maintain a response to a hypomethylating agent (HMA) alone.
Moving Average Crossover: Great News for MEI Pharma Inc. (MEIP)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 06, 7:44AM CST
Moving Average Crossover: Great News for MEI Pharma Inc. (MEIP)?
Fluids Simulation Advancements In ANSYS 15.0 Bring Faster and More Accurate Results to Users
PR Newswire - Fri Dec 20, 6:25AM CST
With faster pre-processing, solver and optimization technologies, users of ANSYS Inc.'s (NASDAQ: ANSS) release 15.0 for fluid dynamics simulation will be able to meet tighter development deadlines and further reduce time to market.
4 Stocks Under $10 to Trade for Breakouts
at The Street - Fri Dec 06, 6:00AM CST
These under-$10 stocks are within range of triggering breakout trades.
MEI Pharma To Host Analyst And Investor Day
PR Newswire - Thu Dec 05, 7:30AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, will host an Analyst and Investor Day on Thursday, December 11, 2013 from 12:00 noon to 2:00 p.m. Eastern time in New York City. The event will feature updates by Daniel P. Gold, Ph.D., President and Chief Executive Officer, and Robert D. Mass, MD, Chief Medical Officer, on the Company's clinical development programs for its lead oncology drug candidates, Pracinostat and ME-344, along with presentations by Dr. Guillermo Garcia-Manero of the MD Anderson Cancer Center and Dr. Jeffrey R. Infante of the Sarah Cannon Research Institute and Tennessee Oncology. A live webcast of the event will be accessible at www.meipharma.com/investor. A replay will be available approximately one hour after its conclusion.
MEI Pharma To Host Annual Meeting Of Stockholders
PR Newswire - Tue Nov 26, 8:00AM CST
MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, will host its Annual Meeting of Stockholders at 10:00 a.m. Central time on Thursday, December 5, 2013 at the W New Orleans, 333 Poydras Street, New Orleans, LA 70130, to consider and vote on certain matters, including the election of three directors, the ratification of the appointment of the Company's independent registered public accounting firm and approval, on an advisory basis, of the compensation of the Company's named executive officers. A live webcast of the meeting will be accessible at www.meipharma.com/investor. A replay will be available approximately one hour after the presentation.
4 Stocks Under $10 Making Big Moves
at The Street - Tue Nov 19, 7:58PM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
MEI Pharma Inc prices public offering at USD8.00 per share
M2 - Mon Oct 28, 6:51AM CDT
Oncology company MEI Pharma Inc (NasdaqCM:MEIP) said on Friday that it has priced an underwritten public offering of 4,375,000 shares of its common stock.
Nasdaq stocks posting largest percentage decreases
AP - Fri Oct 25, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
(0)
(0)MEI Pharma Inc. (MEIP) Stock Research Links
Scroll down for more posts ▼